ALLR News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AL

Mkt Cap

$14.2M

Volume

215.57K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock NowAllarity Therapeutics (ALLR) has formed a hammer chart pattern, suggesting potential trend reversal after recent declines. The stock is supported by strong analyst agreement on raising earnings estimates, with consensus EPS estimates up 13% over the last 30 days. ALLR holds a Zacks Rank #2 (Buy), placing it in the top 20% of rated stocks.Zacks Investment Research · Oct 9, 2026

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line ResearchAllarity Therapeutics expanded its in-house medical laboratory to include proteomics and cell line research capabilities, building on existing transcriptomics and CLIA clinical testing services. The expansion aims to deepen mechanism-of-action research for stenoparib, its dual PARP and WNT pathway inhibitor, while broadening external research services. The company expects cost efficiencies without impacting current cash runway.GlobeNewswire Inc. · Sep 28, 2026

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026Allarity Therapeutics announced it will present a Trial-in-Progress poster on its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster will outline the study design and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The presentation will be led by Principal Investigator Dr. Kathleen N. Moore, a leading expert in gynecologic oncology.GlobeNewswire Inc. · Jun 18, 2026

PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, prostate cancer, and glioblastoma, with approximately 12+ drugs in early to mid-stage development. Recent developments include clinical collaborations and first-in-human trial updates from companies like Acerand Therapeutics and Synnovation Therapeutics.GlobeNewswire Inc. · May 7, 2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficeAllarity Therapeutics announced that the US Patent and Trademark Office has issued a Notice of Allowance for its stenoparib DRP® companion diagnostic patent application. The patent, expected to be formally granted within three months, would provide exclusivity for stenoparib when used with the DRP test at least through 2039. The allowed claims cover methods for predicting clinical benefit and selecting patients most likely to benefit from stenoparib treatment.GlobeNewswire Inc. · Apr 27, 2026

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and CommercializationAllarity Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital to fund Phase 2 ovarian cancer trial completion and advance stenoparib toward FDA approval and commercialization. The financing extends the company's cash runway into mid-2028 and supports preparation for pivotal development and regulatory meetings.GlobeNewswire Inc. · Mar 6, 2026

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for EnrollmentAllarity Therapeutics announced that enrollment is now open for a Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for treating recurrent small cell lung cancer. The trial is conducted in collaboration with the U.S. Department of Veterans Affairs and fully funded through the VA's Special Emphasis Panel on Precision Oncology. The study will assess safety and efficacy at 11 VA sites across the US, with stenoparib's favorable safety profile potentially addressing toxicity limitations seen with previous PARP inhibitor combinations.GlobeNewswire Inc. · Feb 3, 2026

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesAllarity Therapeutics reported significant progress with stenoparib, receiving FDA Fast Track designation for advanced ovarian cancer and presenting clinical trial data showing median overall survival exceeding 25 months for patients receiving the drug twice daily.GlobeNewswire Inc. · Nov 14, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 MonthsAllarity Therapeutics presented promising Phase 2 clinical trial data for stenoparib, a dual PARP and WNT pathway inhibitor for advanced ovarian cancer. The study showed median overall survival exceeding 25 months, with potential benefits for patients with different genetic backgrounds.GlobeNewswire Inc. · Sep 22, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025Allarity Therapeutics' CEO Thomas Jensen will present at the Biomarkers & Precision Medicine 2025 conference in London, discussing stenoparib, a novel dual PARP and WNT pathway inhibitor for cancer treatment, and the company's DRP® companion diagnostic platform.GlobeNewswire Inc. · Sep 17, 2025

AL

ALLRAllarity Therapeutics, Inc. Common Stock

ALLR

Pay with—

Available Balance0.00

Your PositionYou don't own any ALLR yet.

Related Tickers

Earnings